Investors & Partners - Flobiotech

Investors & Partners

This page will soon highlight our strategic collaborations, investment opportunities, and partnership initiatives. Please visit Home or Contact Us for more information.

Advancing Neurodegeneration Research with Long-Term Partners

FloBiotech is a biotechnology company advancing human-relevant disease modeling and precision medicines for neurodegenerative diseases. This page provides an overview for current and prospective investors and partners interested in our platform, programs, and disciplined approach to translation

Why Invest in FloBiotech?

FloBiotech was founded to address a persistent gap in neurodegenerative drug development: the lack of human-relevant systems that reliably translate biological insight into therapeutic progress. By aligning disease modeling and therapeutic strategy within the same biological framework, the company is building a more rigorous path from drug discovery toward therapeutic development.

Our approach is grounded in:

What we are Building

FloBiotech is advancing two complementary pillars:

FloCells™ Platform

A proprietary human brain cell-based platform designed to model tau-driven neurodegenerative disease biology beyond the limitations of traditional models

Clusterin Program

Our therapeutic strategy applies a precision medicine approach to modulate the Clusterin pathway, a shared biological mechanism implicated across multiple neurodegenerative diseases.

Together, these pillars form an integrated framework for discovery, validation, and translational prioritization.

Milestones Achieved

Validation of the FloCells™ Platform

for modeling human-relevant tau pathology

Advancement of the Clusterin Program

supported by genetic rationale and preclinical evidence

IND-Enabling Developments

through structured, data-driven evaluation

Our Roadmap to Precision Neurobiology

From breakthrough validation to global expansion, FloBiotech’s roadmap highlights the key milestones driving scientific, clinical, and commercial growth.

Platform Validation & Standardization

FloCells™ Platform validated and trademark registered.
Next: finalize data standardization, advance clusterin lead selection, and initiate the PET tracer program.

IND-Enabling Studies

Advance FLO-1331 into toxicology and IND-enabling studies, backed by EU and CH patent filings.
Optimize FloCells™ assay validation for scalable screening.

Pipeline Expansion

Expand FloCells™ and Clusterin Program to new tauopathies, including Parkinson’s and Frontotemporal Dementia.
Begin PET tracer optimization and early therapeutic patent work.

Our Supporters & Collaborators

FloBiotech is supported by experienced life-sciences investors and collaborates with leading academic and clinical research groups

The company benefits from active governance and strategic oversight through a board and advisory network with deep expertise across neuroscience, biotech company building, clinical development, and investment

Engaging with FloBiotech

We engage with long-term investors and strategic partners who value scientific rigor, thoughtful company building, and translational discipline

We welcome discussions related to:

Equity Investment

Strategic Pharmaceutical Partnerships

Research Collaborations

Program-leval Licensing or Development Opportunities

Partner With Us

To discuss investment, partnership or collaboration opportunities, we invite you to connect with the FloBiotech team.